Ignite Creation Date:
2025-12-25 @ 3:23 AM
Ignite Modification Date:
2026-01-16 @ 12:34 AM
Study NCT ID:
NCT04870905
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-03-06
First Post:
2021-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
Sponsor:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-01
First Submit QC Date:
None
Study First Post Date:
2021-05-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-02
Last Update Post Date:
2023-03-06
Last Update Post Date Type:
ACTUAL